Evidence map›Paper›PMID 36262350›Full record

ArticleJournal of oncology2022

The lncRNA NEAT1 Inhibits miRNA-216b and Promotes Colorectal Cancer Progression by Indirectly Activating YY1.

Yuping Zhu, Xuanying Wang, Linfeng Zheng, Dechuan Li, Zhuo Liu, Lisong Teng

Abstract read
In one paragraph

Article in Journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuping ZhuZhejiang University, Hangzhou 310058, China.ORCID https://orcid.org/0000-0001-5045-3380
Xuanying WangDepartment of Integrated Chinese and Western Medicine, Cancer Hospital of the University of Chinese Academy of Sciences CHUCAS, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Linfeng ZhengDepartment of Pathology, Cancer Hospital, University of Chinese Academy of Sciences CHUCAS, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Dechuan LiDepartment of Colorectal Surgery, Cancer Hospital of the University of Chinese Academy of Sciences CHUCAS, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Zhuo LiuDepartment of Colorectal Surgery, Cancer Hospital of the University of Chinese Academy of Sciences CHUCAS, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Lisong TengDepartment of Surgery, First Affiliated Hospital of Zhejiang University, Hangzhou 310003, China.ORCID https://orcid.org/0000-0001-6470-9017

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: Real-time quantitative PCR (qRT-PCR) was used to detect the NEAT1, miR-216b, and YIN-YANG-1 (YY1) mRNA levels in CRC tissues and cells, then immunohistochemistry (IHC) was used to detect the expression of YY1 in CRC tissues. Luciferase reporter, qPCR, western blot, and DNA pulldown assays were conducted to study the relationships between NEAT1, miR-216b, and YY1. Flow cytometry analysis was performed for cell cycle and apoptosis analyses, and a colony formation assay was performed to test cell proliferation. Transwell assays were performed to detect cell invasion and migration. Results: The NEAT1 expression was significantly upregulated in CRC tissues compared with its expression in normal tissues, and downregulation of NEAT1 suppressed the proliferation, migration, and invasion of CRC cells. Moreover, we found NEAT1 decreased the miR-216b level directly, and the suppression of miR-216b could inhibit the function of downstream YY1. However, overexpression of YY1 accelerated CRC cell proliferation, migration, and invasion. Conclusion: Our results indicated that NEAT1 acted as an oncogene in CRC and promoted the progression of CRC by directly sponging miR-216 b expression to activate the expression of YY1. The NEAT1/miR-216b/YY1 axis may be a novel therapeutic target for CRC.

Identifiers

PMID36262350
PMCPMC9576420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.